Regulatory comment encouraging FDA to remove barriers to care by allowing patients the choice to opt out of the Clozapine Risk Evaluation and Mitigation Strategy (REMS) after the initial highest risk period and to allow for emergency prescriptions when the administrative barriers are not met.
